Insulin Lispro Market

Published May 16, 2023

Length 150 Pages

SKU # CMI18001202

Description

Insulin Lispro Market, By Type of Insulin Lispro (Rapid-acting Insulin Lispro, Long-acting Insulin Lispro), By Delivery Method (Insulin Pens, Insulin Syringes, Insulin Pumps), By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others), By Age Group (Pediatric Patients, Adult Patients, Geriatric Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Brand (Humalog (Eli Lilly and Company), Admelog (Sanofi), Other Brands), And By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Insulin lispro is used to treat type 1 diabetes (condition in which the body does not produce insulin and cannot control the amount of sugar in the blood) in people who need insulin therapy. It is always used with another type of insulin, unless it is being used in an external insulin pump. Insulin lispro injection products are also used to improve glycemic control in adults with type 2 diabetes who do not respond well to oral medications alone. Insulin lispro is an analog insulin that differs from human insulin with a change in the sequence of two amino acids, proline at B-28 and lysine at B-29. This change prevents insulin from forming dimers and hexamers, which have lower activity than monomeric insulin. Insulin lispro is rapidly absorbed following subcutaneous administration, reaching peak levels within 2-4 hours and remains effective for 18-30 hours.

Market Dynamics:

The global insulin market has grown significantly in recent years, primarily due to an increase in the number of people living with diabetes and technological advancements in the field of insulin delivery devices. This growth is further expected to be supported by factors such as increasing government initiatives to improve healthcare and rising patient demand for insulin, as well as favorable medical reimbursement policies in developed countries.

Changing lifestyles, such as an increased adoption of sedentary habits and unhealthy diets, have resulted in an increased number of people developing diabetes globally. According to the International Diabetes Federation, there are approximately 382 million people who have diabetes worldwide, and this number is expected to rise to 592 million by 2035. This is likely to fuel the demand for insulin, thereby driving market growth.

However, the market was negatively impacted due to lower diagnosis rate during Covid-19 pandemic.

Key features of the study:

This report provides in-depth analysis of the global insulin lispro market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global insulin lispro market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, Sanofi, Novo Nordisk A/S, Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Johnson & Johnson Services, Inc., Biocon Limited, Mylan N.V., Boehringer Ingelheim, International GmbH, Wockhardt Ltd., Lupin Pharmaceuticals, Inc., Bioton S.A., and Ypsomed AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global insulin lispro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin lispro market

Detailed Segmentation:

Global Insulin Lispro Market, By Type of Insulin Lispro

Rapid-acting Insulin Lispro

Long-acting Insulin Lispro

Global Insulin Lispro Market, By Delivery Method

Insulin Pens

Insulin Syringes

Insulin Pumps

Global Insulin Lispro Market, By Indication

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes

Others

Global Insulin Lispro Market, By Age Group

Pediatric Patients

Adult Patients

Geriatric Patients

Global Insulin Lispro Market, By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Insulin Lispro Market, By Brand

Humalog (Eli Lilly and Company)

Admelog (Sanofi)

Other Brands

Global Insulin Lispro Market, By Geography

North America

Europe

Asia Pacific

South America

Middle East & Africa

Company Profiles

Eli Lilly and Company

Sanofi

Novo Nordisk A/S

Merck & Co., Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

AstraZeneca PLC

Johnson & Johnson Services, Inc.

Biocon Limited

Mylan N.V.

Boehringer Ingelheim International GmbH

Wockhardt Ltd.

Lupin Pharmaceuticals, Inc.

Bioton S.A.

Ypsomed AG

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Type of Insulin Lispro; Market Snapshot, By Delivery Method; Market Snapshot, By Indication; Market Snapshot, By Age Group; Market Snapshot, By Distribution Channel; Market Snapshot, By Brand; Market Snapshot, By Geography; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Growing prevalence of diabetes; Decline in demand for insulin during Covid-19 pandemic; Growing launch of new product; Impact Analysis; Key Highlights; Regulatory Scenario; Product launch/Approvals; PEST Analysis; PORTER’s Analysis; Merger and Acquisition Scenario
4. Global Insulin Lispro Market – Impact of Coronavirus (COVID-19) Pandemic: COVID-19 Epidemiology; Supply Side and Demand Side Analysis; Economic Impact
5. Global Insulin Lispro Market , By Type of Insulin Lispro, 2017-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Rapid-acting Insulin Lispro; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn); Long-acting Insulin Lispro; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Bn)
6. Global Insulin Lispro Market , By Delivery Method, 2017-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Insulin Pens; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Insulin Pens; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Insulin Pumps; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
7. Global Insulin Lispro Market , By Indication, 2017-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Type 1 Diabetes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Type 2 Diabetes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Gestational Diabetes; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
8. Global Insulin Lispro Market , By Age Group, 2017-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Pediatric Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Adult Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Geriatric Patients; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion)
9. Global Insulin Lispro Market , By Geriatric Patients, 2017-2030, (US$ Bn): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); 10. Global Insulin Lispro Market , By Brand, 2017-2030, (US$ Bn); Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Humalog (Eli Lilly and Company); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Admelog (Sanofi); Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); Other Brands; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Billion); 11. Global Insulin Lispro Market , By Region, 2017-2030, (US$ Bn); Introduction; Market Share Analysis, By Country, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Country 2017 –2030; Country Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Insulin Lispro, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Delivery Method, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Brand, 2017-2030,(US$ Bn); Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Insulin Lispro, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Delivery Method, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Brand, 2017-2030,(US$ Bn); Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Insulin Lispro, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Delivery Method, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Brand, 2017-2030,(US$ Bn); Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Insulin Lispro, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Delivery Method, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Brand, 2017-2030,(US$ Bn); Middle East & Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type of Insulin Lispro, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Delivery Method, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Brand, 2017-2030,(US$ Bn); 12. Competitive Landscape; Eli Lilly and Company; Company Highlights; Product Portfolio; Key Developments; Financial Performance; Strategies; Sanofi; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Novo Nordisk A/S; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Novo Nordisk A/S; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Novo Nordisk A/S; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; F. Hoffmann-La Roche Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; AstraZeneca PLC; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Johnson & Johnson Services, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Biocon Limited; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Mylan N.V.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Boehringer Ingelheim International GmbH; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Wockhardt Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Lupin Pharmaceuticals, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Bioton S.A.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Ypsomed AG; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Strategies; Analyst Views; 13. Section; Research Methodology; About us; *Browse 24 market data tables and 28 figures on "Global Insulin Lispro Market” - Global forecast to 2030

Pricing

Currency Rates

Single User Email from Publisher $4,500
Site License Fulfilled by Publisher $7,000
Global Site License Email from Publisher $10,000

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now